INS and type 2 diabetes mellitus: The current clinical treatment for T2DM is a continuous subcutaneous insulin infusion, but the repeated insulin injection in the same site can cause local reactions of subcutaneous scleroma, fat atrophy and ache, which limits its widespread application.